WO2001043693A3 - Vaccins polynucleotidiques exprimant la proteine nef de vih-1 optimisee par codons et proteine nef de vih-1 modifiee - Google Patents

Vaccins polynucleotidiques exprimant la proteine nef de vih-1 optimisee par codons et proteine nef de vih-1 modifiee Download PDF

Info

Publication number
WO2001043693A3
WO2001043693A3 PCT/US2000/034162 US0034162W WO0143693A3 WO 2001043693 A3 WO2001043693 A3 WO 2001043693A3 US 0034162 W US0034162 W US 0034162W WO 0143693 A3 WO0143693 A3 WO 0143693A3
Authority
WO
WIPO (PCT)
Prior art keywords
nef
hiv
dna vaccines
codon optimized
modifications
Prior art date
Application number
PCT/US2000/034162
Other languages
English (en)
Other versions
WO2001043693A2 (fr
Inventor
John W Shiver
Xiaoping Liang
Tong-Ming Fu
Original Assignee
Merck & Co Inc
John W Shiver
Xiaoping Liang
Fu Tong Ming
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, John W Shiver, Xiaoping Liang, Fu Tong Ming filed Critical Merck & Co Inc
Priority to CA002393861A priority Critical patent/CA2393861A1/fr
Priority to EP00989282A priority patent/EP1242441A4/fr
Priority to JP2001544634A priority patent/JP2003516741A/ja
Priority to AU25810/01A priority patent/AU782193B2/en
Publication of WO2001043693A2 publication Critical patent/WO2001043693A2/fr
Publication of WO2001043693A3 publication Critical patent/WO2001043693A3/fr
Priority to US11/081,244 priority patent/US20050215508A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques qui comprennent des vaccins ADN Nef de VIH ainsi que la production et l'utilisation de ces vaccins ADN. Les vaccins ADN à base de nef selon l'invention sont administrés par introduction directe dans les tissus d'un vertébré vivant, de préférence chez un homme et expriment la protéine Nef de VIH ou des parties appropriées du point de vue biologique de cette dernière, pour induire une réponse immunitaire des cellules qui reconnaît de manière spécifique le virus de l'immunodéficience humaine (VIH-1). Les molécules d'ADN qui comprennent le cadre de lecture ouvert de ces vaccins ADN sont des molécules d'ADN de synthèse qui codent une protéine Nef optimisée par codons et des dérivés de la protéine Nef de VIH-1 optimisée, y compris les modifications de nef comprenant les peptides principaux du terminal amino, l'élimination du site de myristylation du terminal amino, et/ou la modification du motif dileucine de Nef. Ces modifications peuvent produire des caractéristiques de type sauvage de Nef, telles que la myristylation et la régulation négative de l'hôte CD4.
PCT/US2000/034162 1999-12-17 2000-12-15 Vaccins polynucleotidiques exprimant la proteine nef de vih-1 optimisee par codons et proteine nef de vih-1 modifiee WO2001043693A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002393861A CA2393861A1 (fr) 1999-12-17 2000-12-15 Vaccins polynucleotidiques exprimant la proteine nef de vih-1 optimisee par codons et proteine nef de vih-1 modifiee
EP00989282A EP1242441A4 (fr) 1999-12-17 2000-12-15 Vaccins polynucleotidiques exprimant la proteine nef de vih-1 optimisee par codons et proteine nef de vih-1 modifiee
JP2001544634A JP2003516741A (ja) 1999-12-17 2000-12-15 コドン最適化ＨＩＶ−１Ｎｅｆ及び修飾ＨＩＶ−１Ｎｅｆを発現するポリヌクレオチドワクチン
AU25810/01A AU782193B2 (en) 1999-12-17 2000-12-15 Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef
US11/081,244 US20050215508A1 (en) 1999-12-17 2005-03-16 Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17244299P 1999-12-17 1999-12-17
US60/172,442 1999-12-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/081,244 Continuation US20050215508A1 (en) 1999-12-17 2005-03-16 Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef

Publications (2)

Publication Number Publication Date
WO2001043693A2 WO2001043693A2 (fr) 2001-06-21
WO2001043693A3 true WO2001043693A3 (fr) 2002-02-21

Family

ID=22627710

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/034162 WO2001043693A2 (fr) 1999-12-17 2000-12-15 Vaccins polynucleotidiques exprimant la proteine nef de vih-1 optimisee par codons et proteine nef de vih-1 modifiee

Country Status (5)

Country Link
EP (1) EP1242441A4 (fr)
JP (1) JP2003516741A (fr)
AU (1) AU782193B2 (fr)
CA (1) CA2393861A1 (fr)
WO (1) WO2001043693A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883169B2 (en) 2007-08-16 2014-11-11 Chrontech Pharma Ab Immunogen platform
US9598469B2 (en) 2001-07-05 2017-03-21 Novartis Vaccines And Diagnostics, Inc. HIV-1 south african subtype C env proteins

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
EP1200622A4 (fr) 1999-07-06 2004-12-22 Merck & Co Inc Vaccin contre le vih comprenant un adenovirus vehiculant le gene gag
AU785143B2 (en) 2000-02-04 2006-10-05 Beth Israel Deaconess Medical Center Human immunodeficiency virus vaccine
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
JP4601956B2 (ja) * 2001-09-20 2010-12-22 グラクソ グループ リミテッド Ｈｉｖ−ｇａｇのコドン最適化ｄｎａワクチン
ES2560449T3 (es) 2004-05-28 2016-02-19 Oryxe Una mezcla para administración transdérmica de compuestos de peso molecular bajo y alto
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
CN101040041A (zh) * 2004-09-17 2007-09-19 申特莱恩公司 质粒dna的稳定液体制剂
PL229124B1 (pl) 2015-02-10 2018-06-29 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Szczepionka DNA skierowana przeciwko wirusowi grypy H5N1, zmodyfikowana sekwencja nukleotydowa oraz zastosowanie zmodyfikowanej nukleotydowej sekwencji do wytwarzania szczepionki

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851813A (en) * 1990-07-12 1998-12-22 President And Fellows Of Harvard College Primate lentivirus antigenic compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9456201A (en) * 2000-09-15 2002-03-26 Merck & Co Inc Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851813A (en) * 1990-07-12 1998-12-22 President And Fellows Of Harvard College Primate lentivirus antigenic compositions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GIRARD M.: "New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview", COMPTES RENDUS DE L ACADEMIE DES SCIENCES, SERIE III, SCIENCES DE LA VIE, vol. 322, no. 11, November 1999 (1999-11-01), pages 959 - 966, XP002941094 *
See also references of EP1242441A4 *
TOBERTY T. ET AL.: "Cutting edge: Induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen", J. IMMUNOLOGY, vol. 162, no. 2, 15 January 1999 (1999-01-15), pages 639 - 642, XP002938798 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9598469B2 (en) 2001-07-05 2017-03-21 Novartis Vaccines And Diagnostics, Inc. HIV-1 south african subtype C env proteins
US8883169B2 (en) 2007-08-16 2014-11-11 Chrontech Pharma Ab Immunogen platform

Also Published As

Publication number Publication date
AU2581001A (en) 2001-06-25
EP1242441A2 (fr) 2002-09-25
WO2001043693A2 (fr) 2001-06-21
AU782193B2 (en) 2005-07-07
EP1242441A4 (fr) 2004-04-14
CA2393861A1 (fr) 2001-06-21
JP2003516741A (ja) 2003-05-20

Similar Documents

Publication Publication Date Title
ATE386538T1 (de) Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
DE69435075D1 (de) , die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
WO1998049300A3 (fr) Formes tronquees de proteines apparentees au facteur vegf
HK1053985A1 (zh) 人類多肽引起或導致殺死細胞，包括淋巴腫瘤細胞
WO2004078777A3 (fr) Proteines protegees contre la dipeptidylpeptidase
WO2001043693A3 (fr) Vaccins polynucleotidiques exprimant la proteine nef de vih-1 optimisee par codons et proteine nef de vih-1 modifiee
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
WO2001005825A3 (fr) Nouveaux procedes et materiaux des angiopoietines
DK1025236T3 (da) Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
ATE293169T1 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
HUP0500637A2 (hu) Neublasztin polimer konjugátumai és alkalmazási eljárásai
DE60204224D1 (de) Verwendung bestimmter substituierter pyrrolidone wie z.b. piracetam bei der behandlung von viralen und anderen erkrankungen
HUP0400703A2 (hu) Csökkentett immunogenitású módosított eritropoietin (EPO)
ATE177843T1 (de) Peptomere mit erhöhter immunogenizität
WO2004096856A3 (fr) Famille de proteines secretees
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
WO2000047223A3 (fr) Virus-vaccins
DE60045894D1 (de) Extraktion von polysaccharide aus algenprotein und verwendung davon
EP1316319A4 (fr) Nouvel agent de therapie genique permettant de traiter l'hemophilie b et son procede de preparation
WO2001053324A3 (fr) Nouveaux peptides haptotactiques
HUP0303150A2 (hu) Csökkentett immunogenitású, módosított keratinocita növekedési faktor (KGF)
ZA200108398B (en) Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein.
WO2004050703A8 (fr) Variant d'epissage de l'hormone de croissance hypophysaire humaine
WO2004032863A3 (fr) Formulations orales permettant d'administrer des proteines et des polypeptides
WO2004089980A3 (fr) Vaccin preventif contre le cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000989282

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 25810/01

Country of ref document: AU

Ref document number: 2393861

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 544634

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10149640

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000989282

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 25810/01

Country of ref document: AU